Blüher Matthias, Brennan Aoife M, Kelesidis Theodoros, Kratzsch Jürgen, Fasshauer Mathias, Kralisch Susan, Williams Catherine J, Mantzoros Christos S
Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Diabetes Care. 2007 Feb;30(2):280-5. doi: 10.2337/dc06-1362.
Adiponectin, an adipocyte-secreted hormone, circulates in the serum in several multimeric forms. Compared with total adiponectin, high-molecular weight (HMW) adiponectin has been suggested to be a better predictor of metabolic parameters and insulin sensitivity in humans. Our objective was to compare total adiponectin with HMW adiponectin as predictors of metabolic variables and insulin sensitivity at both baseline and after an exercise intervention.
We obtained blood samples from 60 men and women with normal glucose tolerance (n = 20), impaired glucose tolerance (IGT) (n = 20), or type 2 diabetes (n = 20) at baseline and after 4 weeks of training to measure metabolic variables. Using commercially available assays, we measured plasma total adiponectin using LINCO, Mediagnost, and ALPCO assays and HMW adiponectin using an ALPCO assay.
HMW adiponectin and total adiponectin (ALPCO) had similar ability to predict the presence of insulin resistance. Total adiponectin, as measured by radioimmunoassay (LINCO) and enzyme-linked immunosorbent assay (ELISA) (Mediagnost), correlated most strongly with measures of insulin sensitivity (P < 0.01) and lipid profile (P < 0.01) at baseline, showed greater improvements of adiponectin levels (P < 0.001), was more closely associated with improvements of lipid measures with exercise training (P < 0.01), and more accurately predicted insulin resistance and IGT in comparison with total adiponectin or HMW measured with the ALPCO ELISA.
These results do not support the superiority of HMW over total adiponectin (measured using currently available assays) in assessing metabolic variables at baseline or in response to physical training. Moreover, there are significant differences in the ability of commercially available assays for total adiponectin to predict metabolic variables.
脂联素是一种由脂肪细胞分泌的激素，以多种多聚体形式在血清中循环。与总脂联素相比，高分子量（HMW）脂联素被认为能更好地预测人类的代谢参数和胰岛素敏感性。我们的目的是比较总脂联素和HMW脂联素作为基线和运动干预后代谢变量及胰岛素敏感性预测指标的差异。
我们从60名糖耐量正常（n = 20）、糖耐量受损（IGT）（n = 20）或2型糖尿病（n = 20）的男性和女性中采集基线血样以及训练4周后的血样，以测量代谢变量。使用市售检测方法，我们用LINCO、Mediagnost和ALPCO检测法测量血浆总脂联素，用ALPCO检测法测量HMW脂联素。
HMW脂联素和总脂联素（ALPCO）预测胰岛素抵抗存在的能力相似。通过放射免疫分析（LINCO）和酶联免疫吸附测定（ELISA）（Mediagnost）测得的总脂联素，在基线时与胰岛素敏感性指标（P < 0.01）和血脂谱（P < 0.01）的相关性最强，脂联素水平改善更显著（P < 0.001），与运动训练后血脂指标的改善更密切相关（P < 0.01），并且与用ALPCO ELISA测量的总脂联素或HMW脂联素相比，能更准确地预测胰岛素抵抗和IGT。
这些结果不支持在评估基线或体育锻炼反应时，HMW脂联素优于总脂联素（使用现有检测方法测量）。此外，市售总脂联素检测方法预测代谢变量的能力存在显著差异。
